Posts tagged Roth Capital Partners
Roth starts coverage of 3 companies with novel approaches to AD

Roth Capital Partners initiated coverage of three companies – vtv Therapeutics (NASDAQ:VTVT), Anevex Life Sciences (NASDAQ:AVXL) and Neurotrope Biosciences (NASDAQ:NTRP) - that are developing drugs with novel approaches to Alzheimer’s disease (AD).

Read More
Roth ups GlycoMimetics PT to $35

Roth Capital Partners raised its price target for GlycoMimetics (NASDAQ:GLYC) to $35 from $25 after the company agreed with the Dutch hematological oncology foundation, HOVON, to move towards a 140-patient study of GMI-1271 in combination with decitabine in newly-diagnosed patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) unfit for chemotherapy induction.

Read More